Lecanemab (Leqembi) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1669a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Demenz
Abstract (Originalsprache)
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Lecanemab (Leqembi) for Alzheimer's Disease. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669a
Vancouver
Lecanemab (Leqembi) for Alzheimer's Disease. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669a
BibTeX
@article{euvimed2023,
title = {Lecanemab (Leqembi) for Alzheimer's Disease},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1669a}
}
EUVIMED